Good
Mostly Aligned
Patient Risk:
Low
Summary
Most substantive claims align with the provided FDA label excerpt (indication, fixed-dose combination, and dosing-related concepts), but several claims are non-label regulatory/location statements and two safety/eligibility prompts are not supported by the supplied FDA prescribing information excerpts.
Category Scores
Accurate Statements
Glyxambi contains the active ingredients empagliflozin and linagliptin.
Label Sections 1 and 12.1 state GLYXAMBI is a combination of empagliflozin and linagliptin.
Glyxambi is used in adults with type 2 diabetes to improve blood sugar control.
Label Section 1: GLYXAMBI indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Glyxambi is typically used as an add-on when diet and exercise and other treatments are not enough.
Label Section 1: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (The excerpt provided does not explicitly mention 'other treatments are not enough,' but 'adjunct to diet and exercise' is supported.)
Glyxambi is a fixed-dose combination.
Label Sections 2.2 and 3 describe fixed-dose combination tablets with specific strengths (10 mg/5 mg and 25 mg/5 mg).
Because Glyxambi is a fixed-dose combination, it must be appropriate to the clinician’s selected doses.
Label Sections 2.2 and 3 specify fixed-dose strengths and dose escalation options; clinician dose selection must match available fixed combinations.
In France, access to Glyxambi depends on being prescribed by a healthcare professional.
Not supported or contradicted by the provided FDA label excerpts (regulatory/location statement outside provided label scope).
Glyxambi is marketed in France under the brand name Glyxambi.
Not supported or contradicted by the provided FDA label excerpts (regulatory/location statement outside provided label scope).
Unsupported Statements
In France, patients should ask about eligibility with their kidney function.
The provided FDA excerpts support renal impairment-related limitations (not recommended below eGFR <30), but the claim is framed as a patient instruction in France and is not directly supported as 'patients should ask' by the supplied label text.
In France, patients should ask about eligibility with their other diabetes medicines.
The provided FDA excerpts mention that Table 3 describes clinically relevant interactions, but the supplied excerpt does not support a specific patient instruction to 'ask about eligibility with their other diabetes medicines' as written.
Glyxambi is commercialized in France as a prescription medicine.
Not supported or contradicted by the provided FDA label excerpts (country/regulatory statement outside provided label scope).
In France, access to Glyxambi depends on the product being included in the relevant prescribing/reimbursement framework used by French health authorities and insurers.
Not supported or contradicted by the provided FDA label excerpts (country/regulatory statement outside provided label scope).
Product availability and reimbursement details for Glyxambi can vary over time by indication and local rules.
Not supported or contradicted by the provided FDA label excerpts (country/regulatory statement outside provided label scope).
Contradictions
Important Omissions
No mention of the label-supported contraindication (hypersensitivity to empagliflozin/linagliptin/excipients) or key renal limitation (not recommended for eGFR <30) in the provided response text, despite related claims about 'eligibility.'
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response largely matches general indication and fixed-dose combination concepts from the label. However, two France-specific 'patients should ask' eligibility prompts are not directly supported by the supplied label excerpts and could mislead the focus of patient discussions; no direct contraindication or warning language contradicts the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Two patient-instruction claims (asking about kidney function/other diabetes medicines) are not directly supported by the provided FDA label excerpts as phrased, and several France-specific regulatory/reimbursement statements are outside the scope of the provided FDA label.
Suggested Improvement
Rephrase safety-eligibility statements to mirror label-supported content from the provided excerpts (e.g., renal limitation: not recommended below eGFR <30) rather than 'patients should ask' instructions, and avoid asserting France-specific prescribing/reimbursement details unless supported by the label text provided.